Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that an abstract detailing results from the RAV12 Phase 1/2a trial has been accepted as a poster discussion presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). The presentation is scheduled for May 30, 2008. Dr. Nancy Lewis of the Fox Chase Cancer Center is the abstract's first author and will make the presentation on behalf of the study's participating investigators.

The study, which enrolled 53 patients with adenocarcinomas bearing the RAAG12 antigen, particularly those of gastrointestinal (GI) origin, was conducted at 5 institutions in the US, the Sarah Cannon Cancer Center in Nashville, TN; the Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; the University of Miami Medical Center in Miami, FL; and the Georgetown University Medical Center in Washington, DC.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic dissemination. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12-defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly c
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...early peek at what would turn out to be a major ne...the ceiling. , ,As a physics post-doc at the Unive...olds sawed a hole in the ceiling of an office of t...ting a specially built spectrometer through the ro...ear view of a faint glowing gas that permeates the...
...., a provider of information management systems, ...portfolio management and investment accounting sol...rder processing through trade execution, accountin... reporting. , ,Brookfield-based Fiserv designed e...sing dates and the software is capable of managing...
...ice-fishing net, a polymer sorting machine and a B...of a field of 22 inventions University of Wisconsi...Days , Feb. 12 and 13. , ,The projects competed fo...ototype Prize, both sponsored by UW-Madison alumni...e marketplace. , ,We place quite a bit of weight o...
...2004 Conference kicked off today with a high leve... who traveled to Scottsdale for this event which i... new consumer and enterprise technology products. ... international media, venture capitalists, and vet...reneurs introduce new products, and technologies i...
Other Biology Technology:Journey Leads Astronomer to New Galactic Structure 2Journey Leads Astronomer to New Galactic Structure 3UW-Madison Undergrads Shine at Innovation Days 2Entrepreneurs Preview Liberating Technologies 2Entrepreneurs Preview Liberating Technologies 3
(Date:7/24/2008)...sity College of Medicine, Hershey, Pennsylvania ha...inically important immune response modifier with p...nt on the Opioid Growth Factor (OGF)-OGF receptor ...ted in the August 08 issue of Experimental Biolog...ly used drug that may lead to development of new a...
(Date:7/24/2008)... might tell potential suitors, "I like the way you...r look. But worms send their valentines via signal...earchers are now cracking, according to a study pu... . , Scientists from the University of Florida,...echnology and the U.S. Department of Agriculture h...
(Date:7/24/2008)... storage in western U.S. forests , Active fire ...caused a widespread increase in fire-intolerant tr...ng on trees within western U.S. forests. These fac...to account for much of North America,s carbon sink...s, Fellows and Goulden compare California forest i...
(Date:7/23/2008)...ternationally renowned scientists from 12 countrie...alia and India to address ancient microscopic fos...ing together the world,s best scientists in the fi...liam Schopf, founder and director of the UCLA Inst...for the Study of Evolution and the Origin of Life ...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 1DentaBurst 28TM 29 Freshening Teeth Cleaners Launches Outshine Everyone Video Contest 12052 2Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 1Moving beyond tamoxifen 3A Drug discovery and the future of selective hormone receptor modulators 12049 2French paradox redux 3F US vs French on being full 12046 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 1Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign 12042 2
...ome of patients with type 2 diabetes (DT2) has bee...e of new DNA chip technologies allowing 400,000 DN...s conferring a predisposition to DT2 have been ide...reatic insulin-secreting cells (ZnT8), which is a ...French population was carried out as a French-Brit...
... findings, which are being published the week of F... of the National Academy of Sciences, offer signif...ell as those that lead to abnormal amyloid fibril ...very of novel therapeutic targets for neurodegener... amyloids can play beneficial roles. The subject o...
...ype of protein discovered by Queen’s University re...or antibiotic-resistant bacteria, such as those th... the structure and activity of the protein ?called...rom the departments of Biochemistry and Microbiolo...r new drug development. , “Our group is the fi...
...hers from the Virginia Commonwealth University Mas...arch at the American Association of Cancer Researc...ew combination treatment for chronic lymphocytic l...ant, M.D., Massey,s associate director of translat...d romidepsin (Gloucester Pharmaceuticals) and bort...
Other Biology News:Elucidation of the genome for diabetics with DNA chips 2Elucidation of the genome for diabetics with DNA chips 3Scripps research study reveals structural dynamics of single prion molecules 2Scripps research study reveals structural dynamics of single prion molecules 3Protein discovery targets antibiotic-resistant bacteria 2
Proteinase K Buffer 3.9 ml
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454
Glutathione Agarose Beads 10 ml
Biology Products: